RxDoctor Payments Data

Siva Sankaran, MD

Internal Medicine · Clio, MINPI 1306986252

Payments from drug & device makers

$596in general payments, 2019–2025

Across 9 payments — averaging $66.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$125
  • GSK$113
  • Medtronic$92
  • Neurocrine Biosciences, Inc.$91
  • Novo Nordisk$71
  • Abbott$51
  • plus $52 from 2 others

What the payments were for

  • Food & beverage$596100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$596 in reported general payments places this provider in the 65th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$68,613
Medicare patients
159
Services billed
790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$85,441
JanuviaSitagliptin Phosphate68$82,370
OzempicSemaglutide34$31,287
XareltoRivaroxaban25$30,541
JardianceEmpagliflozin20$26,970
ProliaDenosumab15$26,362
LinzessLinaclotide17$15,574
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$9,095
Metoprolol Succinate312$7,877
Simvastatin547$6,434
Atorvastatin Calcium350$6,241
Levothyroxine Sodium535$6,176
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate28$6,026
Advair DiskusFluticasone Propion/Salmeterol19$5,141
Losartan Potassium265$4,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$36$82,37068 claims
Novo NordiskOzempic$71$31,28734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Clio

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →